Nos chercheur.es publient... / These researchers who make the news…

  • Information publiée le

One more step has been achieved by researchers who demonstrated in lupus mice that in vivo the therapeutic peptide P140 corrects some alterations of lysosomes in the spleen and inhibits the lysosomal uptake of autophagy substrates in liver cells.

Some years ago, The Muller’s team discovered a phosphopeptide called P140, which proved to be protective in lupus, both in a severe murine model of the disease and in patients affected by this dramatic, yet poorly understood, autoimmune syndrome. A few years later, the team showed that P140 targets autophagy, a vital process influencing the cellular death/live balance, involved in the regulation of inflammation and in the biology of immune cells. P140 is the first peptide drug that targets chaperone-mediated autophagy selectively. The direct effect of P140 peptide on this form of autophagy was demonstrated in 2015 using in a unique in vitro system (transfected cells). One more step was achieved in 2020 in showing in lupus mice that in vivo, P140 corrects some alterations of lysosomes in spleen B lymphocytes and inhibits the lysosomal uptake of CMA substrates in liver cells.

 

More information

Back